Smallpox virus plaque phenotypes: genetic, geographical and case fatality relationships

References

1. Aldaz-Carroll L., Whitbeck J. C., Ponce de Leon M., Lou H., Hirao L., Isaacs S. N., Moss B., Eisenberg R. J., Cohen G. H. 2005; Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol 79:6260–6271 [CrossRef]
   [Google Scholar]
2. Appleyard G., Hapel A. J., Boulter E. A. 1971; An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol 13:9–17 [CrossRef]
   [Google Scholar]
3. Bell E., Shamim M., Whitbeck J. C., Sfyroera G., Lambris J. D., Isaacs S. N. 2004; Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325:425–431 [CrossRef]
   [Google Scholar]
4. Blasco R., Moss B. 1992; Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol 66:4170–4179
   [Google Scholar]
5. Davies D. H., Molina D. M., Wrammert J., Miller J., Hirst S., Mu Y., Pablo J., Unal B., Nakajima-Sasaki R. other authors 2007; Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7:1678–1686 [CrossRef]
   [Google Scholar]
6. Engelstad M., Smith G. L. 1993; The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627–637 [CrossRef]
   [Google Scholar]
7. Engelstad M., Howard S. T., Smith G. L. 1992; A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801–810 [CrossRef]
   [Google Scholar]
8. Esposito J. J., Sammons S. A., Frace A. M., Osborne J. D., Olsen-Rasmussen M., Zhang M., Govil D., Damon I. K., Kline R. other authors 2006; Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science 313:807–812 [CrossRef]
   [Google Scholar]
9. Gurt I., Abdalrhman I., Katz E. 2006; Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res 69:158–164 [CrossRef]
   [Google Scholar]
10. Herrero-Martínez E., Roberts K. L., Hollinshead M., Smith G. L. 2005; Vaccinia virus intracellular enveloped virions move to the cell periphery on microtubules in the absence of the A36R protein. J Gen Virol 86:2961–2968 [CrossRef]
    [Google Scholar]
11. Katz E., Wolffe E., Moss B. 2002; Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol 76:11637–11644 [CrossRef]
    [Google Scholar]
12. Katz E., Ward B. M., Weisberg A. S., Moss B. 2003; Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein. J Virol 77:12266–12275 [CrossRef]
    [Google Scholar]
13. Li Y., Carroll D. S., Gardner S. N., Walsh M. C., Vitalis E. A., Damon I. K. 2007; On the origin of smallpox: correlating variola phylogenics with historical smallpox records. Proc Natl Acad Sci U S A 104:15787–15792 [CrossRef]
    [Google Scholar]
14. McIntosh A. A. G., Smith G. L. 1996; Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol 70:272–281
    [Google Scholar]
15. Parkinson J. E., Smith G. L. 1994; Vaccinia virus gene A36R encodes a M _r 43–50 K protein on the surface of extracellular enveloped virus. Virology 204:376–390 [CrossRef]
    [Google Scholar]
16. Payne L. G. 1980; Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 50:89–100 [CrossRef]
    [Google Scholar]
17. Payne L. G., Kristensson K. 1985; Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo . J Gen Virol 66:643–646 [CrossRef]
    [Google Scholar]
18. Putz M. M., Midgley C. M., Law M., Smith G. L. 2006; Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12:1310–1315 [CrossRef]
    [Google Scholar]
19. Rotz L. D., Dotson D. A., Damon I. K., Becher J. A. 2001; Vaccinia (smallpox. vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 501–25
    [Google Scholar]
20. Sanderson C. M., Frischknecht F., Way M., Hollinshead M., Smith G. L. 1998; Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell–cell fusion. J Gen Virol 79:1415–1425
    [Google Scholar]
21. Shida H. 1986; Variants of vaccinia virus hemagglutinin altered in intracellular transport. Mol Cell Biol 6:3734–3745
    [Google Scholar]
22. Smith G. L., Vanderplasschen A., Law M. 2002; The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931
    [Google Scholar]
23. Stanford M. M., McFadden G., Karupiah G., Chaudhri G. 2007; Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol 85:93–102 [CrossRef]
    [Google Scholar]
24. Trindade G. S., Emerson G. L., Carroll D. S., Kroon E. G., Damon I. K. 2007; Brazilian vaccinia viruses and their origins. Emerg Infect Dis 13:965–972 [CrossRef]
    [Google Scholar]
25. Vanderplasschen A., Mathew E., Hollinshead M., Sim R. B., Smith G. L. 1998; Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 95:7544–7549 [CrossRef]
    [Google Scholar]
26. van Eijl H., Hollinshead M., Rodger G., Zhang W. H., Smith G. L. 2002; The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J Gen Virol 83:195–207
    [Google Scholar]
27. Wolffe E. J., Isaacs S. N., Moss B. 1993; Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol 67:4732–4741
    [Google Scholar]
28. Yang H., Kim S. K., Kim M., Reche P. A., Morehead T. J., Damon I. K., Welsh R. M., Reinherz E. L. 2005; Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 115:379–387 [CrossRef]
    [Google Scholar]
29. Zhang W. H., Wilcock D., Smith G. L. 2000; Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence. J Virol 74:11654–11662 [CrossRef]
    [Google Scholar]